Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Cystinosis Research Foundation granted $2.15M in 2013 to researchers investigating cure for cystinosis

Cystinosis Research Foundation granted $2.15M in 2013 to researchers investigating cure for cystinosis

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Omeros doses first patient in second Phase 2 clinical trial of OMS824

RNA interference approach holds great promise for treating cancer and other diseases

RNA interference approach holds great promise for treating cancer and other diseases

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

Omeros announces additional positive data from OMS824 Phase 1 program

Omeros announces additional positive data from OMS824 Phase 1 program

Researchers identify new subgroup of patients suffering from schizophrenia with motor disorders

Researchers identify new subgroup of patients suffering from schizophrenia with motor disorders

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Study reveals neurons in brain can combine signals of individual elements into behavioural sequence

Study reveals neurons in brain can combine signals of individual elements into behavioural sequence

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Research: New target for treating Huntington's and Parkinson's disease

Research: New target for treating Huntington's and Parkinson's disease

Study raises hopes for new drugs to treat brain disorders associated with neurotransmitter imbalance

Study raises hopes for new drugs to treat brain disorders associated with neurotransmitter imbalance

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

Researchers develop new technique to cure human diseases caused by misfolded protein molecules

Researchers develop new technique to cure human diseases caused by misfolded protein molecules

Researchers take important step towards development of future drugs for brain diseases

Researchers take important step towards development of future drugs for brain diseases

Protecting or boosting neurotrophins may slow progression of Huntington's disease

Protecting or boosting neurotrophins may slow progression of Huntington's disease

Attractants prevent maturing nerve cells from migrating into brain

Attractants prevent maturing nerve cells from migrating into brain

Omeros’ OMS302 reduces incidence of miosis during intraocular lens replacement in Phase 3 clinical trial

Omeros’ OMS302 reduces incidence of miosis during intraocular lens replacement in Phase 3 clinical trial

Meclizine drug has the potential to treat certain infectious diseases and cancer

Meclizine drug has the potential to treat certain infectious diseases and cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.